| Evaluation of the implementation of the sigmoid take‐off landmark in the Netherlands SMJA Hazen, TC Sluckin, K Horsthuis, DMJ Lambregts, RGH Beets‐Tan, ... Colorectal Disease 24 (3), 292-307, 2022 | 12 | 2022 |
| A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452 EA Feitsma, YF Janssen, HH Boersma, Y van Sleen, D van Baarle, ... Vaccine 41 (13), 2184-2197, 2023 | 9 | 2023 |
| Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452 YF Janssen, EA Feitsma, HH Boersma, DG Alleva, TM Lancaster, ... Vaccine 40 (9), 1253-1260, 2022 | 9 | 2022 |
| Heterogeneity in Utilization of Optical Imaging Guided Surgery for Identifying or Preserving the Parathyroid Glands—A Meta-Narrative Review EA Feitsma, HM Schouw, ME Noltes, W Heeman, W Kelder, GM van Dam, ... Life 12 (3), 388, 2022 | 4 | 2022 |
| Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes SMJA Hazen, TC Sluckin, MPW Intven, GL Beets, RGH Beets-Tan, ... JAMA oncology 10 (2), 202-211, 2024 | 1 | 2024 |
| Prognostic significance of MRI-detected extramural venous invasion according to grade and response to neo-adjuvant treatment in locally advanced rectal cancer A national cohort … EGM van Geffen, J Nederend, TC Sluckin, SMJA Hazen, K Horsthuis, ... European Journal of Surgical Oncology 50 (6), 108307, 2024 | | 2024 |
| Long‐term restoration of bowel continuity after rectal cancer resection and the influence of surgical technique: A nationwide cross‐sectional study SMJA Hazen, EGM van Geffen, TC Sluckin, GL Beets, HJ Belgers, ... Colorectal disease, 2024 | | 2024 |
| Impact of the new rectal cancer definition on multimodality treatment and interhospital variability: Results from a nationwide cross‐sectional study SMJA Hazen, TC Sluckin, K Horsthuis, DMJ Lambregts, RGH Beets‐Tan, ... Colorectal disease, 2024 | | 2024 |
| Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine DG Alleva, EA Feitsma, YF Janssen, HH Boersma, TM Lancaster, ... npj Vaccines 9 (1), 40, 2024 | | 2024 |
| Phase I Interim Results of a Phase I/II Study of the IgG-Fc Fusion COVID-19 Subunit Vaccine, AKS-452 (preprint) Y Janssen, E Feitsma, H Boersma, D Alleva, T Lancaster, T Sathiyaseelan, ... | | 2021 |
schelto kruijffUMCGVerified email at umcg.nl
